Aurobindo Pharma Limited has announced an investor and analyst presentation scheduled for February 10, 2026, to discuss the company's unaudited financial results for the third quarter and nine months period ended December 31, 2025. The pharmaceutical company communicated this development through official letters to both the National Stock Exchange of India Limited and BSE Limited on February 9, 2026.

Presentation Details and Accessibility

The company has prepared a comprehensive presentation covering its Q3FY26 business and financial highlights, which will be utilized during the investor call. The presentation materials have been made available on the company's official website under the investor relations section.

Key Business Highlights for Discussion

The presentation outlines several significant achievements and developments during Q3FY26. The company reported revenue of ₹8,646 crores with 8.4% year-over-year growth, driven by strong Europe performance and stable US operations despite lower transient product sales.

Regulatory and Product Development Updates

The presentation highlights significant progress in the company's biosimilars business through CuraTeQ Biologics. Notable developments include approvals in regulated markets across Europe, UK, and Canada, with products like Zefyti, Dyruppeg, and Dazublys receiving regulatory clearance.

Financial Position and Strategic Outlook

The company maintained a robust financial position with net cash of USD 251 million as of December 31, 2025, after appropriating funds for the Khandelwal Laboratories acquisition. Research and development expenditure totaled ₹409 crores, representing 4.7% of sales, primarily focused on biosimilars and specialty products development. The presentation emphasizes the company's strategic focus on launch momentum in Europe, execution priorities, and partnerships to scale commercialization across global markets.

Aurobindo pharma Limited has announced its earnings call schedule to discuss the third quarter financial results for FY26. The pharmaceutical company informed stock exchanges about the upcoming investor interaction as part of its regulatory disclosure requirements.

Earnings Call Details

The company has scheduled the earnings call with specific timing and access arrangements for analysts and investors.

Regulatory Compliance

The announcement was made pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company secretary B. Adi Reddy signed the communication digitally on February 2, 2026, ensuring compliance with regulatory disclosure norms.

The notification was simultaneously sent to both major stock exchanges where the company is listed:

• National Stock Exchange of India Limited (Company Code: AUROPHARMA)
• BSE Limited (Company Code: 524804)

Access and Participation

Investors and analysts interested in participating in the earnings call need to pre-register through the provided Zoom link. The company has indicated that the earnings presentation will be made available on its official website following the results announcement.

The call will focus on discussing the unaudited financial results for the third quarter and nine months period ended December 31, 2025, providing stakeholders with insights into the company's operational and financial performance during this period.

Company Information

Aurobindo Pharma Limited operates with its corporate office located at Galaxy, Floors 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad. The company maintains its commitment to regulatory transparency through timely disclosure of material information to investors and market participants.